Skip to main content
Supriya Lifescience Limited logo

Supriya Lifescience Limited — Investor Relations & Filings

Ticker · SUPRIYA ISIN · INE07RO01027 LEI · 894500RBVJX1EOJP0Y02 BSE.NS Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2024-10-29 Regulatory Filings
Country IN India
Listing BSE.NS SUPRIYA

About Supriya Lifescience Limited

https://www.supriyalifescience.com

Supriya Lifescience Limited is a research-driven manufacturer of Active Pharmaceutical Ingredients (APIs) with a focus on diverse therapeutic segments. The company specializes in the production of antihistamines, anti-allergics, vitamins, anesthetics, and anti-asthmatics. Its core product portfolio includes Chlorpheniramine Maleate, Ketamine Hydrochloride, and Salbutamol Sulphate, maintaining a significant global market share in these niche categories. Operating with a strong emphasis on backward integration, the firm ensures supply chain reliability and cost efficiency. The manufacturing infrastructure is compliant with international regulatory standards, including approvals from the USFDA, EDQM, and PMDA. Supriya Lifescience serves a broad international clientele across more than 100 countries, catering to both regulated and semi-regulated markets through its advanced R&D capabilities and commitment to quality excellence.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings
2024-10-29 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated October 28, 2024, announcing the unaudited financial results for the quarter and half year ended September 30, 2024. It contains detailed financial highlights including revenues, gross profit, EBITDA, PAT, and EPS for Q2 FY25 and H1 FY25, along with year-over-year comparisons. The document is about the initial announcement of quarterly financial results and includes key performance metrics and management commentary. It is not a full interim or quarterly report with comprehensive financial statements, but rather a press release summarizing the results. Therefore, the appropriate classification is Earnings Release (ER). The document length (8007 characters) and content support this classification with high confidence.
2024-10-28 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 85% confidence The document is a letter dated October 28, 2024, addressed to stock exchanges (BSE and NSE) informing them about the availability of the audio recording of the company's earnings call held on the same day. It references the earnings call discussing operational and financial performance for the quarter and half year ended September 30, 2024. The document does not contain the transcript itself but provides a link to the recording on the company's website. The document length is short (2435 characters) and serves as an announcement of the availability of the earnings call recording rather than the transcript or detailed financial data. According to the classification rules, announcements about earnings calls or their recordings are best classified as Call Transcript (CT) if the transcript is included, but since this is only an announcement of the recording availability, it is more appropriate to classify it as Regulatory Filings (RNS) because it is a regulatory announcement without the actual transcript or financial data. However, given the subject line explicitly states 'Audio recording of Earnings Call' and it is an official intimation under SEBI regulations, the best fitting category is Call Transcript (CT) as it relates directly to the earnings call content, even though it is an announcement of the recording. The confidence is high because the document clearly references the earnings call and its recording availability, which is closely related to call transcripts.
2024-10-28 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation' and is addressed to stock exchanges pursuant to SEBI regulations, indicating it is a formal communication of a presentation. It contains detailed financial highlights for Q2 and H1 FY25, including revenue, EBITDA, PBT, PAT, margins, business mix, and balance sheet and cash flow statements. The content is structured as a presentation with slides and charts, focusing on financial performance, company overview, and future outlook. The document length is about 15,000 characters, which is consistent with a detailed presentation rather than a brief announcement. There is no indication that this is a full annual or interim report, audit report, or earnings release summary. The presence of forward-looking statements and detailed financial data aligns with an investor presentation. Therefore, the document fits the category of an Investor Presentation (IP).
2024-10-28 English
Financial Result Updates
Regulatory Filings
2024-10-28 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an announcement dated October 21, 2024, informing about an upcoming earnings call scheduled for October 28, 2024, to discuss the operational and financial performance for Q2 and H1 of FY 2024-25. It includes details such as the date, time, management representatives, and dial-in numbers. The document does not contain any actual financial data or results but serves as a notification of the earnings call event. According to the classification rules, such announcements about earnings calls are classified as Call Transcript (CT) only if they contain the full transcript. Since this is only an intimation of the earnings call, it is best classified as a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other categories. The document length is under 5,000 characters and is clearly an announcement, not the report or transcript itself.
2024-10-21 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.